What should a patient be prescribed for long-term treatment following a non-ST elevation myocardial infarction (NSTEMI)?

What should a patient be prescribed for long-term treatment following a non-ST elevation myocardial infarction (NSTEMI)?

• A. Calcium channel blocker
• B. Cardioselective beta blocker
• C. Nitroglycerin
• D. Alpha blocker

Answer: (B)

Following a non-ST elevation myocardial infarction (NSTEMI), the primary goal of long-term treatment is to reduce the risk of future cardiovascular events and manage the underlying ischemic heart disease. Cardioselective beta-blockers are particularly beneficial in this context because they improve outcomes by decreasing heart rate, reducing myocardial oxygen demand, and providing added protection against arrhythmias. In NSTEMI patients, the use of cardioselective beta-blockers has been associated with a decrease in mortality, especially in those with subsequent heart failure, prior myocardial infarction, or other risk factors. These medications help stabilize the heart's workload and can also aid in controlling blood pressure and heart rate, contributing to overall cardiac health. Other options, while potentially useful in specific scenarios, do not have the same level of recommendation for routine long-term therapy following NSTEMI. Calcium channel blockers, for instance, may be used in patients with significant coronary vasospasm or angina but are not first-line after NSTEMI. Nitroglycerin is typically used for acute symptoms rather than as a chronic therapy, and alpha blockers are not standard for this indication and primarily target different pathways and conditions.

Following a non-ST elevation myocardial infarction (NSTEMI), the primary goal of long-term treatment is to reduce the risk of future cardiovascular events and manage the underlying ischemic heart disease. Cardioselective beta-blockers are particularly beneficial in this context because they improve outcomes by decreasing heart rate, reducing myocardial oxygen demand, and providing added protection against arrhythmias.

In NSTEMI patients, the use of cardioselective beta-blockers has been associated with a decrease in mortality, especially in those with subsequent heart failure, prior myocardial infarction, or other risk factors. These medications help stabilize the heart's workload and can also aid in controlling blood pressure and heart rate, contributing to overall cardiac health.

Other options, while potentially useful in specific scenarios, do not have the same level of recommendation for routine long-term therapy following NSTEMI. Calcium channel blockers, for instance, may be used in patients with significant coronary vasospasm or angina but are not first-line after NSTEMI. Nitroglycerin is typically used for acute symptoms rather than as a chronic therapy, and alpha blockers are not standard for this indication and primarily target different pathways and conditions.